期刊文献+

联合检测蛋白ERCC1、Rad51和P53的表达与预测晚期非小细胞肺癌铂类药物化疗疗效的相关性研究 被引量:3

Correlation study on test the expression of ERCC1,Rad51 and P53 protein with the effect of Platinum drugs chemotherapy for late non-small cell lung cancer
下载PDF
导出
摘要 目的:检测ERCC1、Rad51和P53在晚期非小细胞肺癌中的表达,探讨其临床意义和与铂类药物化疗疗效的相关性。方法选取我院2012年6月~2013年6月诊断为晚期非小细胞肺癌的68例患者病理学标本,采用免疫荧光组织化学染色法检测晚期非小细胞肺癌患者标本和外周淋巴血细胞中ERCC1、Rad51和P53的表达,观察ERCC1、Rad51和P53在晚期非小细胞肺癌患者标本和外周淋巴血细胞中表达的相关性;给予患者2~4个疗程铂类为基础的标准化疗方案,评价ERCC1、Rad51和P53蛋白的表达与化疗疗效相关性。结果晚期非小细胞肺癌患者标本和外周淋巴血细胞中ERCC1、Rad51和P53阳性率(分别为42.6%、35.3%和45.6%)和阴性表达率(分别为33.8%、27.9%和38.2%)相同,呈显著正相关(均P<0.05);ERCC1、Rad51和P53蛋白表达在患者年龄、性别、TNM分期、病理类型间无统计学意义(P<0.05);ERCC1阳性表达患者铂类药物化疗后总有效率为41.2%,显著低于阴性患者化疗后总有效率73.9%(P<0.05);Rad51阳性表达患者化疗后总有效率33.3%显著低于阴性表达患者化疗后总有效率63.2%(P<0.05);P53阳性表达患者铂类药物化疗后总有效率为29.0%,显著低于阴性患者化疗后总有效率53.8%(P<0.05)。结论检测晚期非小细胞肺癌患者外周淋巴血细胞中ERCC1、Rad51和P53表达可很好反映其在癌组织中的表达情况;ERCC1、Rad51和P53表达较低的患者铂类药物治疗有效率更好,ERCC1、Rad51和P53对化疗疗效的预测为负相关。 Objective To test the expression of ERCC1,Rad51 and P53 protein in late non-small cell lung cancer and explore the clinical significance and the correlation with the effect of Platinum drugs chemotherapy. Methods The pathology specimens of 68 patients with late non-small cell lung cancer in our hospital from June 2012 to June 2013 were collected,used immunofluorescence histochemical staining method to test the expression of ERCC1,Rad51 and P53 in pathology specimens of late non-small cell lung cancer and peripheral lymphoid cells,the correlation between the expression in late non-small cell lung cancer and peripheral lymphoid cells was observed.Patients were treated by platinum standard chemotherapy regimens for 2-4weeks, the correlation between the expression of ERCC1,Rad51 and P53 with effect of Platinum drugs chemotherapy was evaluated. Results The positive rate (42.6%、35.3% and 45.6% respectively)and negative rate(33.8%、27.9% and 38.2% respectively)of ERCC1,Rad51 and P53 protein in late non-small cell lung cancer and peripheral lymphoid cells were same,there was a significant positive correlation(all P 〈 0.05).There was no significant of the expression of ERCC1,Rad51 and P53 in age/Sex,TNM stage and pathological types(P〈0.05).The total effective rate of patients with ERCC1 positive expression after platinum drugs chemotherapy was 41.2% and significant lower than the effective rate(73.9%) of patients with ERCC1 negative expression(P〈0.05);The total effective rate of patients with Rad51 positive expression after platinum drugs chemotherapy was 33.3% and significant lower than the effective rate(63.2%) of patients with Rad51 negative expression(P 〈 0.05);The total effective rate of patients with P53positive expression after platinum drugs chemotherapy was 29.0% and significant lower than the effective rate(58.3%) of patients with P53 negative expression(P 〈 0.05). Conclusion Test the expression of ERCC1,Rad51 and P53 protein in peripheral lymphoid cells of patients with late non-small cell lung cancer and explore can reflect the expression in the cancer tissue very well,the effect of Platinum drugs chemotherapy for patients with ERCC1 negative expression is more better.There has a negative correlation between the expression of ERCC1,Rad51 and P53 protein between the effect of Platinum drugs chemotherapy.
作者 许柏松 冯耘
出处 《中国医药科学》 2014年第23期30-33,180,共5页 China Medicine And Pharmacy
关键词 晚期非小细胞肺癌 ERCC1 RAD51 P53 铂类药物 有效率 相关性 Late non-small cell lung cancer ERCC 1 Rad51 P53 Platinum drugs Effective rate Correlation
  • 相关文献

参考文献17

  • 1徐志巧,张燕.联合检测蛋白ERCC1、Rad51和P53的表达与预测晚期非小细胞肺癌铂类药物化疗的疗效[J].医药论坛杂志,2011,32(1):122-124. 被引量:2
  • 2Froesch P,Martucci F.Management of non-small cell lung cancer in the elderly[J].Eur J Intern Med,2014,31.
  • 3Jett JR,Carr LL.Targeted therapy for non-small cell lung cancer[J].Am J Respir Crit Care Med,2013,188(8):907-912.
  • 4Maimon C.Rose,Elina Kostyanovskaya,R.Stephanie Huang.Pharmacogenomics of Cisplatin Sensitivity in Non-small Cell Lung Cancer[J].Genomics, Proteomics & Bioinformatics,2014,12(5):198-209. 被引量:6
  • 5Cubukcu E,Fatih Olmez O.et al.Immunohistochemical expression of excision repair cross-complementing 1(ERCC1)in non-small-cell lung cancer:implications for patient outcome[J].Clin Transl Oncol,2011,13(11):826-830.
  • 6Ko JC,Chen HJ,et al.HSP90 inhibition induces cytotoxicity via down-regulation of Rad51 expression and DNA repair capacity in non-small cell lung cancer cells[J].Regul Toxicol Pharmacol,2012,64(3):415-424.
  • 7Kasinski AL,Kelnar K,et al.A combinatorial micro RNA therapeutics approach to suppressing non-small cell lung cancer[J].Oncogene,2014,1.
  • 8杨桂芬,朱虹.第7版肺癌TNM分期及影像学在其评估中的价值[J].放射学实践,2012,27(7):803-806. 被引量:19
  • 9非小细胞肺癌临床实践指南(中国版)[M].2010年,(第一版).
  • 10Wachters FM,Wong LS,Timens W,et a1.ERCC1,h Rad5 1,and BRCA1 protein expression in relation ttumor response and survial of stage Ill/IV NSCLC pa-tients treated with chemotherapy[J].Lung Cancer,2005,50(2):211-219.

二级参考文献28

  • 1范玮,张海龙,吴晓明.核苷酸切除修复基因XPA反义RNA增强肺癌细胞对顺铂的敏感性[J].癌症,2005,24(4):403-407. 被引量:3
  • 2金问森,金一尊.Rad51的异常表达与肿瘤治疗[J].国际肿瘤学杂志,2006,33(10):721-724. 被引量:2
  • 3Lord RV, Brabender J, Gandara D, et al. Low ERCC1 expression correlates with prolonged survival after cispl- atin plus gemcitabine chemotherapy in non -small - cell lung cancer[ J ]. Clin Cancer Res, 2002, 8 ( 7 ) : 2286- 2291.
  • 4Siddik ZH. Cisplatin: mode of eytotoxic and molecular basis of resistance[ J]. Oncogene,2003,22(47 ) :7265- 7279.
  • 5Wachters FM, Wong LS, Timens W, et al. ERCC1, hRadSl,and BRCA1 protein expression in relation to tumor response and survial of stage Ill/IV NSCLC patients treated with chemotherapy [ J ]. Lung Cancer, 2005, 50(2) :211-219.
  • 6Lord RV, Brabender J, Gandara D, et al. Low ERCC1 expression crorrelates with prolonged survival after cisplatin plus gemcitabine chemotherapy in Non - small cell lung cancer[ J ]. Clin Cancer Res, 2002,8 ( 7 ) : 2286- 2291.
  • 7Isla D, Sarries C, Rosell R, et al. Single nucleotide polymorphisms and outcome in docetaxol -cisplatin- treated advanced non - small lung cancer [ J ]. Ann On-col, 2004,15 ( 8 ) : 1194-203.
  • 8Ryu JS, Hong YC, Han HS, et al. Association between polymorphisms of ERCC 1 and XPD and survival in non -small lung cancer patients treated with combination chemotherapy[J]. Lung Cancer, 2004, 44(3) :311-6.
  • 9Takenaka T, Yoshino I, Kouso H, et al. Combined evaluation of RadS1 and ERCCl expressions for sensitivi- ty to platinum agents in non - small cell lung cancer [ J]. Int J Cancer,2007,121 (4) :895-900.
  • 10Qiao GB, Wu YL, Yang XN, et al. High -level expression of RadSl is an independent prognostic marker of surival in non - small - cell lung cancer patients [ J]. BrJ Cancer,2005,93 ( 1 ) : 137-143.

共引文献24

同被引文献23

引证文献3

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部